Navigation Links
Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
Date:10/29/2007

Partnership quadruples distribution of Corvalen(R) (D-ribose) products to

health practitioners

MINNEAPOLIS, and GREEN BAY, Wis., Oct. 29 /PRNewswire/ -- Bioenergy Life Science -- The Ribose Company, and Integrative Therapeutics, Inc. (ITI), a division of Enzymatic Therapy Inc. (ETI), today announced that they have entered into an exclusive co-marketing alliance. ITI will now sell the Corvalen(R) line of products, developed by Bioenergy Life Science, to its established health care practitioners.

Corvalen(R) is a medical food containing pure, proprietary D-ribose, a unique sugar made by the body to synthesize many important compounds, including DNA, RNA, and, most importantly, ATP, the "energy currency" of the cells. ATP (adenosine triphosphate) is critical to health and maintaining normal energy-dependent body functions. Ribose is the essential component in the making of ATP and as a medical food, Corvalen(R) is prescribed and used under the direction of a licensed healthcare practitioner.

Clinical research has shown that Corvalen(R) can help effectively manage diseases in which there is a deficiency in energy (i.e., ATP). D-Ribose has already been shown to increase functional capacity for patients with congestive heart failure (CHF), decrease fatigue caused by Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS), and enhance energy for athletes and others who need a natural boost.

"We are terrifically enthused about advancing the entire science of wellness with Bioenergy Life Science as our alliance partner," said Randy Rose, president and CEO of Enzymatic Therapy, Inc. "The research and product development synergies we have together will bring a number of patient and consumer health solutions forward that dramatically improve the quality of life for many."

Tom VonderBrink, president and chief operating officer of Bioenergy Life Science, concurred. "We are thrilled about the agreement with this quality leading company as it quadruples the number of representatives educating health care practitioners on the value of this significant emerging therapy," he said. "D-ribose is already changing the lives of many suffering from chronic energy-depleting conditions. It's also improving the quality of life for baby boomers as they reach the prime of their lives. Our collaboration will mean that more people will have access to this exciting breakthrough."

Research published in the Journal of Alternative and Complementary Medicine (12:9, 2006, 35-40) suggests that Corvalen(R) (D-ribose) provides metabolic support to accelerate cellular energy recovery and normal cellular functioning for patients with Chronic Fatigue Syndrome and fibromyalgia. "The research helped us pinpoint the energy-building benefit of Corvalen(R), and how it substantially reduces the debilitating symptoms of these devastating conditions," said Jacob Teitelbaum, MD, board-certified internist and author of the pilot study. "I think this study, and follow-up research now underway, will show Corvalen(R) to be one of the most important new nutrients evaluated over the next few years."

Bioenergy Inc., http://www.bioenergy.com, parent of Bioenergy Life Science, is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose in health and wellness. Bioenergy Life Science products include Bioenergy Ribose(TM), a functional ingredient in the active lifestyle market; and Corvalen(R), and CorvalenM(R), clinical nutrition products giving metabolic support to patients with heart and muscle disease. Bioenergy Ribose is non-GMO certified. The product is also manufactured under the supervision of the Kashruth Division of the Orthodox Union. Toll-free order line is 866-267-8253.

Integrative Therapeutics, Inc., based in Green Bay, Wisconsin http://www.integrativeinc.com, is North America's leading manufacturer and distributor of proprietary, natural, dietary supplements for medical professionals and their patients. It is one of the first and only dietary supplement manufacturers that's an FDA-registered drug establishment and also a certified organic processor. For more than 30 years, ITI products have been used by medical professionals and researchers around the world. The company's products and ingredients are collectively the subject of over 2,500 independent, peer-reviewed-published clinical trials and studies. ITI's products are extensively used in research supported by major medical universities, hospital research centers and government agencies including the National Institutes of Health and the Veteran's Administration. Toll-free order line is 800-931-1709.


'/>"/>
SOURCE Bioenergy Life Science
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Federal bioenergy lab will give Wisconsin a chance to shine
2. UW-Madison to receive $125M for bioenergy research center
3. Advantages of Roche Applied Science amplification products
4. Tools for Proteomic Science II
5. Exploiting the Life Science Data Explosion to Speed New Drug Discovery
6. Food science: increasing crop yields
7. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
8. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
9. NanoRite Innovation Center opens with small science, big promise
10. Midwest life science stocks kept sizzling in Q2
11. Perscitus Biosciences secures $250K Commerce loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced today ... National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work ... throughout the drug regulatory review process. , “Adding Diane Dorman is just the ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
Breaking Biology News(10 mins):